Compare Synchrony Financial (SYF) vs 10X Genomics Inc (TXG) Price & Performance

Synchrony Financial (SYF) trades at $73.41, down 0.29% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a net income margin of 24.06% and ROE of 22.98%, supported by consistent earnings beats in recent quarters. Recent Q2 2026 results highlighted record purchase volume and a raised EPS outlook, though cash flow trends indicate a net outflow projection for 2026. Analyst consensus remains strongly bullish with a $86.38 price target.

The outlook for SYF is positive based on fundamental strength and analyst confidence, but near-term technical pressure and macroeconomic sensitivity pose risks. Investment appeal lies in its low P/E of 7.6 and dividend yield, though investors should monitor credit quality and interest rate impacts given its consumer lending focus.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.